{
  "guideline": {
    "id": "PA166104984",
    "name": "Annotation of DPWG Guideline for phenytoin and CYP2C9",
    "source": "DPWG",
    "version": 30,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104984",
    "relatedChemicals": [
      {
        "id": "PA450947",
        "name": "phenytoin",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA126",
        "name": "cytochrome P450 family 2 subfamily C member 9",
        "symbol": "CYP2C9"
      }
    ],
    "recommendation": true,
    "guidelineGenes": [
      {
        "alleles": [
          {
            "id": 1451444662,
            "_label": "*1",
            "function": {
              "term": "Normal function (CYP2C9*1)",
              "termId": "alleleFunction:1451444660"
            }
          },
          {
            "id": 1451444637,
            "_label": "*2",
            "function": {
              "term": "Decreased function (CYP2C9*2)",
              "termId": "alleleFunction:1451444630"
            }
          },
          {
            "id": 1451444663,
            "_label": "*3",
            "function": {
              "term": "Decreased function (CYP2C9*3)",
              "termId": "alleleFunction:1451444680"
            }
          },
          {
            "id": 1451444631,
            "_label": "*4",
            "function": {
              "term": "Decreased function",
              "termId": "haplotypeTags:1445558331"
            }
          },
          {
            "id": 1451444632,
            "_label": "*5",
            "function": {
              "term": "Decreased function",
              "termId": "haplotypeTags:1445558331"
            }
          },
          {
            "id": 1451444633,
            "_label": "*6",
            "function": {
              "term": "No function",
              "termId": "haplotypeTags:1445558515"
            }
          },
          {
            "id": 1451444634,
            "_label": "*8",
            "function": {
              "term": "Decreased function",
              "termId": "haplotypeTags:1445558331"
            }
          },
          {
            "id": 1451444635,
            "_label": "*11",
            "function": {
              "term": "Decreased function",
              "termId": "haplotypeTags:1445558331"
            }
          },
          {
            "id": 1451444636,
            "_label": "*12",
            "function": {
              "term": "Decreased function",
              "termId": "haplotypeTags:1445558331"
            }
          },
          {
            "id": 1451444664,
            "_label": "*13",
            "function": {
              "term": "Decreased function",
              "termId": "haplotypeTags:1445558331"
            }
          }
        ],
        "gene": {
          "chr": {
            "id": "PA504",
            "name": "chr10",
            "symbol": null
          },
          "strand": "plus",
          "id": "PA126",
          "name": "cytochrome P450 family 2 subfamily C member 9",
          "symbol": "CYP2C9"
        }
      }
    ]
  },
  "annotationGroups": [
    {
      "id": "PA166243742",
      "name": "Normal Metabolizer",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "No",
        "termId": "rxChange:1448602495"
      },
      "genePhenotypes": [
        "CYP2C9:Normal function (CYP2C9*1)/Normal function (CYP2C9*1)"
      ],
      "metabolizerStatus": {
        "id": 1451445435,
        "html": "<p>Normal Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451445436,
        "html": "<p>The guideline does not provide a recommendation for phenytoin in normal metabolizers.</p>\n"
      },
      "implications": {
        "id": 1451445434,
        "html": "<p>The guideline does not provide a description of the impact of a normal metabolizer phenotype on phenytoin.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166243741",
      "name": "Intermediate Metabolizer",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Yes",
        "termId": "rxChange:1448602497"
      },
      "genePhenotypes": [
        "CYP2C9:Decreased function/Normal function (CYP2C9*1)",
        "CYP2C9:No function/Normal function (CYP2C9*1)"
      ],
      "metabolizerStatus": {
        "id": 1451838084,
        "html": "<p>Intermediate Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451838085,
        "html": "<ol>\n<li>The loading dose does not need to be adjusted.</li>\n<li>For the other doses, use 75% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.</li>\n<li>Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or rash) occur.</li>\n</ol>\n"
      },
      "implications": {
        "id": 1451838083,
        "html": "<p>Genetic variation reduces conversion of phenytoin to inactive metabolites. This increases the risk of side effects.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166243743",
      "name": "*1/*2",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Yes",
        "termId": "rxChange:1448602497"
      },
      "genePhenotypes": [
        "CYP2C9:Decreased function (CYP2C9*2)/Normal function (CYP2C9*1)"
      ],
      "metabolizerStatus": {
        "id": 1451838087,
        "html": "<p>Intermediate Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451838089,
        "html": "<ol>\n<li>The loading dose does not need to be adjusted.</li>\n<li>For the other doses, use 75% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.</li>\n<li>Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or rash) occur.</li>\n</ol>\n"
      },
      "implications": {
        "id": 1451838086,
        "html": "<p>Genetic variation reduces conversion of phenytoin to inactive metabolites. This increases the risk of side effects.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166243744",
      "name": "*1/*3",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Yes",
        "termId": "rxChange:1448602497"
      },
      "genePhenotypes": [
        "CYP2C9:Decreased function (CYP2C9*3)/Normal function (CYP2C9*1)"
      ],
      "metabolizerStatus": {
        "id": 1451838091,
        "html": "<p>Intermediate Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451838093,
        "html": "<ol>\n<li>The loading dose does not need to be adjusted.</li>\n<li>For the other doses, use 75% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.</li>\n<li>Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or, especially in Asian patients, rash) occur.</li>\n</ol>\n"
      },
      "implications": {
        "id": 1451838090,
        "html": "<p>Genetic variation reduces conversion of phenytoin to inactive metabolites. This increases the risk of side effects. The life-threatening cutaneous side effects Stevens-Johnson Syndrome and toxic epidermal necrolysis may occur, especially in Asian patients.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166243761",
      "name": "Poor Metabolizer",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Yes",
        "termId": "rxChange:1448602497"
      },
      "genePhenotypes": [
        "CYP2C9:Decreased function (CYP2C9*2)/No function",
        "CYP2C9:Decreased function (CYP2C9*3)/No function",
        "CYP2C9:Decreased function/Decreased function",
        "CYP2C9:Decreased function/Decreased function (CYP2C9*2)",
        "CYP2C9:Decreased function/Decreased function (CYP2C9*3)",
        "CYP2C9:Decreased function/No function",
        "CYP2C9:No function/No function"
      ],
      "metabolizerStatus": {
        "id": 1451838095,
        "html": "<p>Poor Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451838096,
        "html": "<ol>\n<li>The loading dose does not need to be adjusted.</li>\n<li>For the other doses, use 40-50% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.</li>\n<li>Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or rash) occur.</li>\n</ol>\n"
      },
      "implications": {
        "id": 1451838094,
        "html": "<p>Genetic variation reduces conversion of phenytoin to inactive metabolites. This increases the risk of side effects.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166243781",
      "name": "*2/*2",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Yes",
        "termId": "rxChange:1448602497"
      },
      "genePhenotypes": [
        "CYP2C9:Decreased function (CYP2C9*2)/Decreased function (CYP2C9*2)"
      ],
      "metabolizerStatus": {
        "id": 1451838098,
        "html": "<p>Poor Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451838100,
        "html": "<ol>\n<li>The loading dose does not need to be adjusted.</li>\n<li>For the other doses, use 50% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.</li>\n<li>Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or rash) occur.</li>\n</ol>\n"
      },
      "implications": {
        "id": 1451838097,
        "html": "<p>Genetic variation reduces conversion of phenytoin to inactive metabolites. This increases the risk of side effects.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166243782",
      "name": "*2/*3",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Yes",
        "termId": "rxChange:1448602497"
      },
      "genePhenotypes": [
        "CYP2C9:Decreased function (CYP2C9*2)/Decreased function (CYP2C9*3)"
      ],
      "metabolizerStatus": {
        "id": 1451838102,
        "html": "<p>Poor Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451838104,
        "html": "<ol>\n<li>The loading dose does not need to be adjusted.</li>\n<li>For the other doses, use 50% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.</li>\n<li>Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or rash) occur.</li>\n</ol>\n"
      },
      "implications": {
        "id": 1451838101,
        "html": "<p>Genetic variation reduces conversion of phenytoin to inactive metabolites. This increases the risk of side effects.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166243801",
      "name": "*3/*3",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Yes",
        "termId": "rxChange:1448602497"
      },
      "genePhenotypes": [
        "CYP2C9:Decreased function (CYP2C9*3)/Decreased function (CYP2C9*3)"
      ],
      "metabolizerStatus": {
        "id": 1451838106,
        "html": "<p>Poor Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451838108,
        "html": "<ol>\n<li>The loading dose does not need to be adjusted.</li>\n<li>For the other doses, use 40% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.</li>\n<li>Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or, especially in Asian patients, rash) occur.</li>\n</ol>\n"
      },
      "implications": {
        "id": 1451838105,
        "html": "<p>Genetic variation reduces conversion of phenytoin to inactive metabolites. This increases the risk of side effects. The life-threatening cutaneous side effects Stevens-Johnson Syndrome and toxic epidermal necrolysis may occur, especially in Asian patients.</p>\n"
      },
      "activityScore": null
    }
  ],
  "citations": [
    {
      "pmid": "21412232",
      "title": "Pharmacogenetics: from bench to byte--an update of guidelines.",
      "authors": [
        "Swen J J",
        "Nijenhuis M",
        "de Boer A",
        "Grandia L",
        "Maitland-van der Zee A H",
        "Mulder H",
        "Rongen G A P J M",
        "van Schaik R H N",
        "Schalekamp T",
        "Touw D J",
        "van der Weide J",
        "Wilffert B",
        "Deneer V H M",
        "Guchelaar H-J"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2011
    }
  ],
  "version": "2023-03-05-00-25"
}